Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
European Commission
MedTech
Illumina gets go-ahead from EU to part ways with Grail
The DNA sequencing giant still has the freedom to choose between selling the cancer blood test developer outright or pursuing an independent spinout.
Conor Hale
Apr 12, 2024 10:11am
EU orders Illumina to split from Grail as penance for $8B deal
Oct 12, 2023 11:14am
EU order for Illumina to divest Grail coming soon: reports
Oct 11, 2023 10:33am
Ipsen still out of luck as EC rejects rare disease drug
Jul 20, 2023 6:32am
Illumina hit by record €432M fine for false start on Grail deal
Jul 12, 2023 9:24am
Illumina faces EU's maximum fine for closing Grail deal: report
Jan 13, 2023 11:00am